Stockscreener 앱 받기
270.26
0.88%
-2.39
시간 외 거래:
270.26
전일 마감가:
$272.65
열려 있는:
$275.56
하루 거래량:
128.79K
Relative Volume:
0.47
시가총액:
$7.84B
수익:
$290.51M
순이익/손실:
$89.16M
주가수익비율:
90.39
EPS:
2.99
순현금흐름:
$119.18M
1주 성능:
+0.98%
1개월 성능:
-0.69%
6개월 성능:
+88.18%
1년 성능:
+78.60%
1일 변동 폭
$269.40
$275.56
1주일 범위
$260.03
$280.00
52주 변동 폭
$122.80
$295.98
Krystal Biotech Inc Stock (KRYS) Company Profile
명칭
Krystal Biotech Inc
전화
(412) 586-5830
주소
2100 WHARTON STREET, PITTSBURGH, PA
Compare KRYS vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
KRYS
Krystal Biotech Inc
|
270.26 | 7.91B | 290.51M | 89.16M | 119.18M | 2.99 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Krystal Biotech Inc Stock (KRYS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-06 | 업그레이드 | Citigroup | Neutral → Buy |
| 2025-03-05 | 개시 | Jefferies | Buy |
| 2024-08-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2023-11-20 | 개시 | Goldman | Buy |
| 2023-10-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2023-10-12 | 개시 | Citigroup | Buy |
| 2023-09-07 | 개시 | Berenberg | Buy |
| 2023-04-18 | 개시 | Stifel | Buy |
| 2023-02-28 | 업그레이드 | Goldman | Neutral → Buy |
| 2022-08-25 | 다운그레이드 | Goldman | Buy → Neutral |
| 2022-01-18 | 개시 | BofA Securities | Buy |
| 2021-07-20 | 업그레이드 | Goldman | Neutral → Buy |
| 2020-09-18 | 개시 | B. Riley FBR | Buy |
| 2020-06-04 | 개시 | Evercore ISI | Outperform |
| 2019-09-24 | 개시 | Goldman | Neutral |
| 2019-08-06 | 재확인 | H.C. Wainwright | Buy |
| 2019-06-24 | 재확인 | Chardan Capital Markets | Buy |
| 2019-06-24 | 재확인 | H.C. Wainwright | Buy |
| 2019-05-30 | 개시 | Guggenheim | Buy |
| 2018-09-11 | 개시 | Cantor Fitzgerald | Overweight |
모두보기
Krystal Biotech Inc 주식(KRYS)의 최신 뉴스
Krystal Biotech: Flawless Vyjuvek Launch - AlphaStreet News
3 Growth Companies Insiders Are Betting On - simplywall.st
Krystal Biotech (NASDAQ:KRYS) CAO Sells $3,401,750.00 in Stock - MarketBeat
Alps Advisors Inc. Decreases Stock Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech co-founder makes Forbes 250 innovators list - Mugglehead Investment Magazine
Krystal Biotech wins FDA RMAT status for lung cancer therapy - MSN
Krystal Biotech: KB707 Program Bolstered By RMAT And 2nd Half 2026 Update (NASDAQ:KRYS) - Seeking Alpha
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 - The Manila Times
Krystal Biotech to Report Fourth Quarter and Full Year 2025 Financial Results on February 17, 2026 - GlobeNewswire Inc.
FDA grants RMAT designation to Krystal Biotech’s lung cancer therapy By Investing.com - Investing.com South Africa
Krystal Biotech (KRYS) Gains FDA RMAT Status for Innovative Lung Cancer Therapy - GuruFocus
Krystal Biotech wins FDA RMAT status for cancer drug (KRYS) - Seeking Alpha
Krystal Biotech Receives FDA RMAT Designation for KB707 - Intellectia AI
Krystal Biotech Says US FDA Grants Regenerative Medicine Advanced Therapy Designation to Lung Cancer Treatment - marketscreener.com
FDA grants RMAT designation to Krystal Biotech’s lung cancer therapy - Investing.com
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of ... - Caledonian Record
Krystal Biotech Announces RMAT Designation Granted by FDA to KB707 for the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer - The Manila Times
FDA backs KB707 lung cancer immunotherapy with RMAT designation - Stock Titan
Krystal Biotech (NASDAQ:KRYS) Stock Rating Lowered by Zacks Research - MarketBeat
Krystal Biotech, Inc. (KRYS) Earnings Expected to Grow: Should You Buy? - MSN
Krystal Biotech, Inc. (NASDAQ:KRYS) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Federated Hermes Inc. Cuts Holdings in Krystal Biotech, Inc. $KRYS - MarketBeat
Vyjuvek Growth Powers Krystal Biotech’s (KRYS) Huge Upward Analyst Target Price Revision - Insider Monkey
Krystal Biotech (BIT:1KRYS) Price Target Increased by 11.47% to 252.42 - Nasdaq
Assessing Krystal Biotech (KRYS) Valuation After Analyst Optimism On Vyjuvek Expansion And Ophthalmic Pipeline - Sahm
Goldman Sachs Raises Price Target for Krystal Biotech (KRYS) | K - GuruFocus
Atle Fund Management AB Acquires 22,033 Shares of Krystal Biotech, Inc. $KRYS - MarketBeat
Krystal Biotech stock price target raised to $327 by Goldman Sachs - Investing.com Canada
Earnings Miss: Is Krystal Biotech Inc. impacted by rising ratesJuly 2025 Short Interest & Safe Entry Point Alerts - mfd.ru
5 Stocks With Recent Price to Strengthen Your Portfolio - The Globe and Mail
Krystal Biotech, Inc. $KRYS Shares Acquired by EFG Asset Management North America Corp. - MarketBeat
Krystal Biotech (KRYS) is on the Move, Here's Why the Trend Could be Sustainable - sharewise.com
Clear Street raises Krystal Biotech stock price target on KB801 potential - Investing.com Canada
Are you looking for a top momentum pick? Why Krystal Biotech, Inc. (KRYS) is a great choice - MSN
Assessing Krystal Biotech (KRYS) Valuation As Analyst Upgrades And Earnings Optimism Gain Traction - Sahm
Are You Looking for a Top Momentum Pick? Why Krystal Biotech, Inc. (KRYS) is a Great Choice - Yahoo Finance
Krystal Biotech, Inc. $KRYS Shares Sold by Maryland State Retirement & Pension System - MarketBeat
SG Americas Securities LLC Cuts Position in Krystal Biotech, Inc. $KRYS - MarketBeat
Bank of America Increases Krystal Biotech (NASDAQ:KRYS) Price Target to $318.00 - MarketBeat
KRYS Sees New Price Target as B of A Securities Raises Outlook | - GuruFocus
Nasdaq Moves: Is Caribou Biosciences Inc. backed by strong institutional buyingSell Signal & Low Drawdown Investment Strategies - baoquankhu1.vn
Rate Cut: What drives Krystal Biotech Incs stock price2025 Trading Recap & Risk Controlled Stock Pick Alerts - baoquankhu1.vn
What does Wall Street think about Krystal Biotech (KRYS)? - MSN
Krystal Biotech, Inc. (KRYS) Stock Analysis: Evaluating the Healthcare Innovator’s Growth Potential - DirectorsTalk Interviews
What Does Wall Street Think About Krystal Biotech (KRYS)? - Finviz
Krystal Biotech (KRYS) Is Up 9.0% After Positive Interim Data From Inhaled CF Gene Therapy Study - Sahm
Krystal Biotech gets expanded FDA approval for Vyjuvek - MSN
Krystal Biotech: Beyond VYJUVEK Commercialization (NASDAQ:KRYS) - Seeking Alpha
Recent price trend in Krystal Biotech (KRYS) is your friend, here's why - MSN
Assessing Krystal Biotech (KRYS) Valuation After Strong Recent Share Price Momentum - Sahm
Krystal Biotech (KRYS) Is Up 5.9% After Positive KB407 CF Gene Therapy Update and CORAL-3 Plans - Sahm
Krystal Biotech Inc (KRYS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.24%
0.19%
자본화:
|
볼륨(24시간):